Edwards Lifesciences
EW
$86.07
-0.98%
Edwards Lifesciences Corp is a global leader in structural heart disease medical devices, specializing in surgical tissue heart valves, transcatheter aortic valve replacement (TAVR), and transcatheter mitral and tricuspid therapies. The company holds a dominant market position in TAVR, with a strong pipeline in emerging valve technologies and about 60% of sales from outside the US. The current investor narrative centers on the potential expansion of Medicare coverage for TAVR procedures, which could significantly broaden the addressable market, alongside robust demand for its innovative heart valve therapies as evidenced by recent beat-and-raise quarters. However, the stock has faced volatility due to competitive pressures and broader market concerns, making it a focal point for both growth and risk assessment.…
EW
Edwards Lifesciences
$86.07
Related headlines
Investment Opinion: Should I buy EW Today?
Rating: Buy. Edwards Lifesciences is a high-quality growth company with a dominant position in TAVR, accelerating revenue growth, and a clear catalyst in Medicare expansion. The consensus rating is 'Buy' with an average target price of $100.96, implying ~17% upside from the current price of $86.07.
Sign up to view all
EW 12-Month Price Forecast
The AI model assesses EW as bullish over the next 12 months, driven by strong fundamental momentum and a clear regulatory catalyst. The main uncertainty is the timing and scope of Medicare expansion, which could significantly impact growth. The model would upgrade to high confidence if revenue growth exceeds 20% and Medicare expansion is confirmed. Conversely, a downgrade to neutral would occur if revenue growth falls below 10% or if competitive pressures intensify.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Edwards Lifesciences's 12-month outlook, with a consensus price target around $100.96 and implied upside of +17.3% versus the current price.
Average Target
$100.96
0 analysts
Implied Upside
+17.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $110
Analyst target range
The target price range is $84.00 (low) to $110.00 (high), indicating a wide spread of 31% from low to high, which reflects uncertainty about the pace of TAVR market expansion and competitive dynamics. The high target of $110 assumes successful Medicare coverage expansion and continued market leadership, while the low target of $84 suggests potential margin compression or slower adoption. Recent institutional ratings show no downgrades, with firms like Mizuho, RBC Capital, and Citigroup maintaining positive ratings, and no recent changes, indicating stable sentiment. The wide range suggests that while the consensus is bullish, there is significant debate about the timing and magnitude of catalysts.
Bulls vs Bears: EW Investment Factors
Edwards Lifesciences presents a compelling growth story with accelerating revenue, high margins, and a potential regulatory catalyst in Medicare expansion. However, the stock trades at a premium valuation and has recently underperformed the market. The bull case is stronger given the fundamental momentum and clear catalyst, but the key tension is whether the market's high growth expectations can be met. If Medicare expansion materializes and growth continues to accelerate, the stock could re-rate higher; if not, valuation compression is a real risk.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 16.7% YoY to $1.65B, up from 13.1% growth in Q4 2025, indicating accelerating demand for structural heart devices. This beat-and-raise quarter underscores robust market traction.
- High-Margin Business Model: Gross margin stands at 78.1% and operating margin at 27.0%, reflecting strong pricing power and operational efficiency. These margins are among the highest in the medical device sector, supporting profitability.
- Medicare Coverage Expansion Catalyst: A U.S. agency proposal to expand and simplify Medicare coverage for TAVR procedures is a significant positive catalyst. As the market leader, Edwards is well-positioned to benefit from a broader addressable patient population.
- Strong Balance Sheet: Debt-to-equity is only 0.07 and current ratio is 3.72, indicating minimal leverage and ample liquidity. This financial flexibility supports R&D investment and potential strategic moves.
Bearish
- Elevated Valuation: Trailing PE is 46.3x and forward PE is 25.5x, which is a premium to the broader market. The market is pricing in significant earnings growth, leaving little room for disappointment.
- Recent Price Weakness: The stock is down 6.4% in the past month and has underperformed the S&P 500 over the past year (8.5% vs 18.2%). This relative weakness may indicate waning momentum or sector rotation.
- Competitive Pressures: The TAVR market is becoming more competitive with entrants like Medtronic and Boston Scientific. Any market share loss could pressure growth and margins, as reflected in the wide analyst target range.
- Dependence on Regulatory Approvals: The bull case hinges on Medicare coverage expansion, which is not yet finalized. Delays or unfavorable policy changes could significantly impact growth expectations.
EW Technical Analysis
Edwards Lifesciences is currently in a recovery phase after a significant pullback, with the stock trading at $86.07 as of July 31, 2026, up 8.52% over the past year but down 6.44% in the last month. The price sits at 72.3% of its 52-week range (low: $72.30, high: $96.29), indicating it has recovered from the lows but remains below the highs, suggesting a potential value opportunity if the uptrend resumes. The 52-week low of $72.30 was tested in early 2026, and the stock has since rallied, but the recent pullback from the July high of $95.18 shows resistance at higher levels.
Beta
0.85
0.85x market volatility
Max Drawdown
-13.2%
Largest decline past year
52-Week Range
$72-$96
Price range past year
Annual Return
+8.5%
Cumulative gain past year
| Period | EW Return | S&P 500 |
|---|---|---|
| 1m | -6.4% | +0.3% |
| 3m | +2.5% | +4.0% |
| 6m | +5.8% | +8.3% |
| 1y | +8.5% | +20.2% |
| ytd | +0.9% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EW Fundamental Analysis
Edwards Lifesciences reported Q1 2026 revenue of $1.6486 billion, a 16.7% year-over-year increase, driven by strong growth in Transcatheter Heart Valves (revenue of $1.1973 billion) and Transcatheter Mitral and Tricuspid Therapies ($175.1 million). The company's revenue has been consistently growing, with Q1 2026 marking the highest quarterly revenue in the past year, up from $1.4127 billion in Q1 2025. This growth is accelerating, as the YoY growth rate of 16.7% is higher than the previous quarter's 13.1% (Q4 2025 revenue of $1.5696 billion vs. Q4 2024's $1.3858 billion), indicating robust demand for its structural heart devices.
Quarterly Revenue
$1.6B
2026-03
Revenue YoY Growth
+16.7%
YoY Comparison
Gross Margin
78.2%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EW Overvalued?
Given that Edwards Lifesciences is profitable, the primary valuation metric is the price-to-earnings (PE) ratio. The trailing PE is 46.33x, while the forward PE is 25.50x, indicating that the market expects significant earnings growth. The gap between trailing and forward PE suggests an expected EPS growth of approximately 82% over the next year, which is optimistic but supported by the company's strong revenue growth and margin expansion. The PEG ratio is negative (-0.63) due to negative earnings growth in the past, but this is not meaningful given the recent turnaround.
PE
46.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 27x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Edwards has minimal debt (debt-to-equity of 0.07) and a strong current ratio of 3.72, so balance sheet risk is low. However, the company's profitability is highly dependent on sustained revenue growth; Q4 2025 net margin dropped to 5.8% due to one-time charges, highlighting earnings volatility. The high gross margin of 78% could face pressure if competition intensifies or if pricing power erodes. Additionally, the company's heavy R&D spending (16% of revenue) is essential for innovation but could strain margins if revenue growth slows.